We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Werfen Completes Immucor Acquisition to Expand Leadership in Specialized Diagnostics

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: Werfen had reached an agreement in November 2022 to acquire Immucor for USD 2 billion (Photo courtesy of Werfen)
Image: Werfen had reached an agreement in November 2022 to acquire Immucor for USD 2 billion (Photo courtesy of Werfen)

Werfen (Barcelona, Spain) has successfully completed the acquisition of Immucor, Inc. (Norcross, GA, USA) after receiving the required regulatory and antitrust approvals. In November 2022, Werfen reached an agreement to acquire Immucor, a privately held in vitro diagnostics (IVD) company with a strong presence in the global Transfusion and Transplant markets, for approximately USD 2 billion. The Transfusion and Transplant product lines complement Werfen's existing Hemostasis, Acute Care, and Autoimmunity business lines, expanding its portfolio of Specialized Diagnostic solutions for hospitals and clinical laboratories.

With the integration of Immucor, Werfen has expanded its presence as a company of reference in the Specialized Diagnostics market and grown its portfolio of diagnostic solutions for hospitals and clinical laboratories. Additionally, Werfen will have seven technology centers and employ more than 7,000 people worldwide; with a direct presence in over 30 countries and across more than 100 territories through distributors.

"During our more than 50-year history, we have demonstrated our strong commitment to expand our IVD business through organic growth, complemented with highly strategic acquisitions," said Carlos Pascual, CEO of Werfen.

Related Links:
Werfen 
Immucor, Inc. 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.